<unk>  (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).<unk>  is manufactured by Amgen and marketed as Vectibix. It was originally developed by Abgenix Inc. In 2014, Amgen and Illumina entered into an agreement to develop a companion diagnostic to accompany<unk> .
Panitumumab
Necitumumab
Cetuximab
Sorafenib
Dasatinib
Neratinib
Fostamatinib
Tucatinib